查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618278

胃癌治療藥市場評估:治療類型·類型·藥物類別·給藥途徑·流通管道·各地區的機會及預測 (2018-2032年)

Stomach Cancer Treatment Market Assessment, By Treatment Type, By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 237 Pages | 商品交期: 3-5個工作天內

價格

全球胃癌治療市場規模預計將從2024年的54.1億美元成長到2032年的145.9億美元，預測期內複合年增長率為13.20%。

近年來，胃癌治療市場獲得了巨大的關注。由於認識的提高、患病率的增加以及新療法的開發，預計該疾病將繼續以驚人的速度增長。

胃癌主要起源於胃黏膜，有慢性胃炎、幽門螺旋桿菌感染、吸菸、高鹽飲食等多種危險因子。遺傳傾向，包括某些遺傳性疾病，也會導致胃癌的發生。胃癌的治療通常會根據個體的階段和部位而有所不同。治療主要是手術，包括透過部分或全胃切除術去除腫瘤和周圍組織。化療也是一種常見的方法，包括在手術前進行新輔助治療以縮小腫瘤，以及在手術後進行輔助治療以去除任何殘留的癌細胞。在某些情況下，放射療法與化學療法一起使用以有效根除癌細胞。先進的治療方法包括標靶治療，使用選擇性作用於癌細胞特定特徵或增強針對腫瘤的免疫反應的藥物。此外，正在進行的臨床研究正在增加市場潛力。

本報告提供全球胃癌治療藥的市場調查，彙整市場定義和概要，市場規模的轉變·預測，各種區分·地區/各主要國家的詳細分析，產業結構，影響市場成長因素的分析，案例研究，競爭情形，主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球胃癌治療藥市場展望

  • 市場規模的分析·預測
  • 市場佔有率的分析·預測
    • 各治療類型
    • 各類型
    • 各類藥物
    • 各給藥途徑
    • 各流通管道
    • 各地區
    • 企業佔有率分析
  • 市場地圖分析

第5章 北美的胃癌治療藥市場展望

  • 市場規模的分析·預測
  • 市場佔有率的分析·預測
  • 各國市場評估
    • 美國
    • 加拿大
    • 墨西哥

第6章 歐洲的胃癌治療藥市場展望

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 波蘭

第7章 亞太地區的胃癌治療藥市場展望

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章 南美的胃癌治療藥市場展望

  • 巴西
  • 阿根廷

第9章 中東·非洲的胃癌治療藥市場展望

  • 沙烏地阿拉伯
  • UAE
  • 南非
  • 以色列

第10章 供需分析

第11章 價值鏈分析

第12章 波特的五力分析

第13章 大環境分析

第14章 價格分析

第15章 市場動態

  • 推動市場要素
  • 市場課題

第16章 市場趨勢·展開

第17章 法律規範和革新

  • 臨床試驗
  • 法規當局的認證

第18章 專利的形勢

第19章 案例研究

第20章 競爭情形

  • 前五名公司的競爭矩陣
  • 前五名公司的SWOT分析
  • 前十大企業的形勢
    • Novartis AG
    • Pfizer, Inc.
    • Mylan N.V. (Viatris Inc.)
    • F. Hoffmann La Roche Ltd.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd
    • Samsung Bioepis Co., Ltd.
    • Bristol Myers Squibb Company

第21章 策略性建議

第22章 關於本公司·免責聲明

Product Code: MX12428

Global stomach cancer treatment market is projected to witness a CAGR of 13.20% during the forecast period 2025-2032, growing from USD 5.41 billion in 2024 to USD 14.59 billion in 2032. The stomach cancer treatment market has gained significant traction in recent years. It is anticipated to keep growing at a notable pace owing to rising awareness, growing prevalence, and development of novel therapies.

Stomach cancer, or gastric cancer, primarily comes from the stomach lining and has multiple risk factors, among which are chronic gastritis, Helicobacter pylori infection, smoking, and dietary components like high salt intake. Genetic predispositions, including certain hereditary conditions, also contribute to its establishment. The treatment for stomach cancer often varies according to the individual stage and location. Treatment mostly focuses on surgery, which involves the removal of the tumor and surrounding tissue by partial or total gastrectomy. Chemotherapy is another common method that can be applied before surgery-neoadjuvant-to shrink the tumors or after surgery-adjuvant-to eliminate any residual cancer cells. In some instances, radiation therapy is used along with chemotherapy to ensure that the cancer cells are eradicated effectively. Advances include targeted therapies, which make use of drugs selective for particular characteristics of cancer cells or which enhance the immune response against the tumor. Furthermore, ongoing clinical research enhances the potential of the market.

For instance, in October 2023, according to an article published in the Annals of Surgical Oncology, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel and cisplatin are well tolerated and are associated with favorable oncologic and perioperative outcomes. This new approach to chemotherapy more than doubles the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the abdominal cavity.

Rising Prevalence of Stomach Cancers Brings Growth in Stomach Cancer Treatment Market

The prevalence of stomach cancer has been on the rise in recent years owing to different causal factors like genetic components, dietary changes, drastic lifestyle changes, and enhanced exposure to carcinogens. Specific reasons for stomach cancer infection in the stomach, long-standing acid reflux, and eating a lot of salty foods. As these causal factors are growing day by day with changing societal scenarios, the incidence of stomach cancer is also anticipated to keep rising. The incidence rate of stomach cancer is expected to decline slightly or remain stagnant in developed regions like North America and Europe, while it is anticipated to increase in developing regions like Africa and Asia. As per the American Cancer Society's estimates for stomach cancer in the United States in 2024, about 16,160 cases in men and 10,730 cases in women are anticipated to be diagnosed. Additionally, around 10,880 deaths are expected from this type of cancer, with 6,490 men and 4,390 women affected. Stomach cancer represents about 1.5% of all new cancer diagnoses in the United States each year.

Growing Drug Development Supports Market Expansion

Growth in drug development is significantly boosting stomach cancer treatment market growth by developing innovative therapies that enhance patient outcomes and offering alternative treatment options. Targeted therapies and immunotherapies represent the most significant recent breakthroughs that have established several new drugs, including trastuzumab and zolbetuximab, targeted at specific molecular characteristics of cancer, such as HER2 and CLDN18.2. These therapies do not only provide alternatives for patients who do not respond to traditional chemotherapy but also demonstrate improved efficacy and reduced side effects, so they are increasingly adopted in clinical practice. Furthermore, ongoing clinical trials would be significant for the findings of new combinations of existing treatments, optimization of dosing regimens, and discovery of novel agents that may further improve survival rates.

For instance, in June 2023, AstraZeneca plc's MATTERHORN Phase III trial demonstrated that combining Imfinzi (durvalumab) with standard FLOT chemotherapy significantly improves pathologic complete response (pCR) in patients with resectable gastric and gastroesophageal junction cancers. The interim analysis showed a statistically meaningful increase in pCR compared to chemotherapy alone. The trial will continue to evaluate event-free survival and overall survival while safety profiles remain consistent with previous findings, indicating a potential new treatment approach for these cancers.

Adenocarcinoma Segment to Dominate the Stomach Cancer Treatment Market

The segment of gastric adenocarcinoma is expected to lead the market in stomach cancer treatment due to several compelling reasons. One such reason is the fact that gastric adenocarcinoma is the most common type of stomach cancer, and its growing prevalence catalyzes this market trend. As indicated by the International Agency for Research on Cancer, the annual burden of gastric cancer is expected to increase to about 1.8 million new cases and 1.3 million deaths by 2040, which should fuel the demand for effective treatments. In addition, advancements in targeted therapies and immunotherapy, especially the use of PD-1 inhibitors, are increasing the efficacy and consumption of their treatments. These have also made clinical trials increasingly successful, encouraging investments and studies in this field. Lastly, biosimilars, like trastuzumab, are expected to increase the number of treatment options and availability further. Consequently, the gastric adenocarcinoma segment is expected to capture a substantial market share, reflecting the continuous evolution of treatment strategies in line with rising incidence rates and technological advances in oncology.

North America Dominates Stomach Cancer Treatment Market

North America leads the stomach cancer treatment market due to several key factors. The region has a significant number of gastric cancer cases; the American Cancer Society estimates stomach cancer cases in the United States for 2024 to be about 26,890 new cases of stomach cancer (16,160 in men and 10,730 in women) and about 10,880 deaths from stomach cancer (6,490 men and 4,390 women). This rising incidence drives demand for effective treatment options. North America benefits from cutting-edge technology and research facilities, which facilitate the development and approval of innovative therapies. For instance, recent FDA approvals for new cancer drugs underscore the region's robust pharmaceutical landscape. This growth is further supported by increasing clinical trials and product launches to enhance treatment efficacy. With the growing economic position of North America on all fronts, particularly the healthcare sector, the market is anticipated to keep growing in the upcoming years.

Future Market Scenario (2025-2032F)

The most recent advancements in immunotherapy are significantly shaping the face of the stomach cancer treatment market. Among the most promising is immune checkpoint inhibitor (ICI) therapy, which has been impressively effective in clinical trials, such as nivolumab and pembrolizumab. These interact with the patient's immune cells to enhance their fight against cancer cells by improving survival in cases of advanced gastric cancer. Apart from ICIs, others emerging as effective strategies are adoptive cell therapies and cancer vaccines. For example, tumor-infiltrating lymphocyte (TIL) therapy has shown a remarkable increase in survival rates when combined with conventional treatments. More research is also being conducted on the antibody-drug conjugates (ADCs) that target particular biomarkers such as claudin18.2 for even more personalized treatment.

Key Players Landscape and Outlook

Companies in the market are engaged in strategic initiatives such as partnerships and product launches to enhance their market presence and address the rising demand for effective treatments. Recent advancements in the market include regulatory approvals and acquisitions.

In October 2024, Astellas Pharma Inc.'s gastric cancer therapy, zolbetuximab (marketed as Vyloy), received approval from the U.S. FDA. The therapy earlier received approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) in August 2024. This first-in-class monoclonal antibody targets claudin 18.2-positive tumors in adults with locally advanced or metastatic gastric and gastroesophageal junction cancers. The therapy is to be used in combination with standard chemotherapy, offering a new treatment option that may extend patient survival and improve outcomes in this challenging cancer type.

In February 2024, AbbVie Inc. completed its acquisition of ImmunoGen Inc., which added ImmunoGen's flagship antibody-drug conjugate, ELAHERE, which targets folate receptor-alpha positive platinum-resistant ovarian cancer, to AbbVie's oncology portfolio. The deal aimed to enhance AbbVie's cancer treatment capabilities and expand its pipeline across various solid tumors and hematologic malignancies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Stomach Cancer Treatment Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Treatment Type
      • 4.2.1.1. Immunotherapy
      • 4.2.1.2. Targeted Therapy
        • 4.2.1.2.1. Biologics
          • 4.2.1.2.1.1. Keytruda
          • 4.2.1.2.1.2. Herceptin
          • 4.2.1.2.1.3. Enhertu
          • 4.2.1.2.1.4. Cyramza
          • 4.2.1.2.1.5. Vitrakvi
          • 4.2.1.2.1.6. Rozlytrek
          • 4.2.1.2.1.7. Vyloy
          • 4.2.1.2.1.8. Others
        • 4.2.1.2.2. Biosimilar
          • 4.2.1.2.2.1. Ogivri
          • 4.2.1.2.2.2. Herzuma
          • 4.2.1.2.2.3. Ontruzant
          • 4.2.1.2.2.4. Trazimera
          • 4.2.1.2.2.5. Kanjinti
          • 4.2.1.2.2.6. Others
      • 4.2.1.3. Chemotherapy
        • 4.2.1.3.1. Capecitabine
        • 4.2.1.3.2. Cisplatin
        • 4.2.1.3.3. Fluorouracil (5-FU)
        • 4.2.1.3.4. Oxaliplatin
        • 4.2.1.3.5. Others
      • 4.2.1.4. Others
    • 4.2.2. By Type
      • 4.2.2.1. Adenocarcinomas
      • 4.2.2.2. Gastrointestinal Stromal Tumors (GISTs)
      • 4.2.2.3. Gastroesophageal Junction Cancer
    • 4.2.3. By Drug Class
      • 4.2.3.1. PD-1/PD-L1 Inhibitors
      • 4.2.3.2. HER2 Antagonists
      • 4.2.3.3. VEGFR2 Antagonists
      • 4.2.3.4. Other Drug Classes
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacies
      • 4.2.5.2. Specialty and Retail Pharmacies
      • 4.2.5.3. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Treatment Type
    • 4.3.2. By Type
    • 4.3.3. By Drug Class
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Stomach Cancer Treatment Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Treatment Type
      • 5.2.1.1. Immunotherapy
      • 5.2.1.2. Targeted Therapy
        • 5.2.1.2.1. Biologics
          • 5.2.1.2.1.1. Keytruda
          • 5.2.1.2.1.2. Herceptin
          • 5.2.1.2.1.3. Enhertu
          • 5.2.1.2.1.4. Cyramza
          • 5.2.1.2.1.5. Vitrakvi
          • 5.2.1.2.1.6. Rozlytrek
          • 5.2.1.2.1.7. Vyloy
          • 5.2.1.2.1.8. Others
        • 5.2.1.2.2. Biosimilar
          • 5.2.1.2.2.1. Ogivri
          • 5.2.1.2.2.2. Herzuma
          • 5.2.1.2.2.3. Ontruzant
          • 5.2.1.2.2.4. Trazimera
          • 5.2.1.2.2.5. Kanjinti
          • 5.2.1.2.2.6. Others
      • 5.2.1.3. Chemotherapy
        • 5.2.1.3.1. Capecitabine
        • 5.2.1.3.2. Cisplatin
        • 5.2.1.3.3. Fluorouracil (5-FU)
        • 5.2.1.3.4. Oxaliplatin
        • 5.2.1.3.5. Others
      • 5.2.1.4. Others
    • 5.2.2. By Type
      • 5.2.2.1. Adenocarcinomas
      • 5.2.2.2. Gastrointestinal Stromal Tumors (GISTs)
      • 5.2.2.3. Gastroesophageal Junction Cancer
    • 5.2.3. By Drug Class
      • 5.2.3.1. PD-1/PD-L1 Inhibitors
      • 5.2.3.2. HER2 Antagonists
      • 5.2.3.3. VEGFR2 Antagonists
      • 5.2.3.4. Other Drug Classes
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Injectable
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital Pharmacies
      • 5.2.5.2. Specialty and Retail Pharmacies
      • 5.2.5.3. Others
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Stomach Cancer Treatment Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Treatment Type
          • 5.3.1.2.1.1. Immunotherapy
          • 5.3.1.2.1.2. Targeted Therapy
          • 5.3.1.2.1.2.1. Biologics
          • 5.3.1.2.1.2.1.1. Keytruda
          • 5.3.1.2.1.2.1.2. Herceptin
          • 5.3.1.2.1.2.1.3. Enhertu
          • 5.3.1.2.1.2.1.4. Cyramza
          • 5.3.1.2.1.2.1.5. Vitrakvi
          • 5.3.1.2.1.2.1.6. Rozlytrek
          • 5.3.1.2.1.2.1.7. Vyloy
          • 5.3.1.2.1.2.1.8. Others
          • 5.3.1.2.1.2.2. Biosimilar
          • 5.3.1.2.1.2.2.1. Ogivri
          • 5.3.1.2.1.2.2.2. Herzuma
          • 5.3.1.2.1.2.2.3. Ontruzant
          • 5.3.1.2.1.2.2.4. Trazimera
          • 5.3.1.2.1.2.2.5. Kanjinti
          • 5.3.1.2.1.2.2.6. Others
          • 5.3.1.2.1.3. Chemotherapy
          • 5.3.1.2.1.3.1. Capecitabine
          • 5.3.1.2.1.3.2. Cisplatin
          • 5.3.1.2.1.3.3. Fluorouracil (5-FU)
          • 5.3.1.2.1.3.4. Oxaliplatin
          • 5.3.1.2.1.3.5. Others
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Type
          • 5.3.1.2.2.1. Adenocarcinomas
          • 5.3.1.2.2.2. Gastrointestinal Stromal Tumors (GISTs)
          • 5.3.1.2.2.3. Gastroesophageal Junction Cancer
        • 5.3.1.2.3. By Drug Class
          • 5.3.1.2.3.1. PD-1/PD-L1 Inhibitors
          • 5.3.1.2.3.2. HER2 Antagonists
          • 5.3.1.2.3.3. VEGFR2 Antagonists
          • 5.3.1.2.3.4. Other Drug Classes
        • 5.3.1.2.4. By Route of Administration
          • 5.3.1.2.4.1. Oral
          • 5.3.1.2.4.2. Injectable
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital Pharmacies
          • 5.3.1.2.5.2. Specialty and Retail Pharmacies
          • 5.3.1.2.5.3. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Stomach Cancer Treatment Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Stomach Cancer Treatment Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Stomach Cancer Treatment Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Stomach Cancer Treatment Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Novartis AG
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Pfizer, Inc.
    • 20.3.3. Mylan N.V. (Viatris Inc.)
    • 20.3.4. F. Hoffmann La Roche Ltd.
    • 20.3.5. Eli Lilly and Company
    • 20.3.6. Merck & Co., Inc.
    • 20.3.7. Teva Pharmaceutical Industries Ltd.
    • 20.3.8. Celltrion Healthcare Co., Ltd
    • 20.3.9. Samsung Bioepis Co., Ltd.
    • 20.3.10. Bristol Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 3. Global Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 4. Global Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 5. Global Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 6. Global Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 7. Global Stomach Cancer Treatment Market Share (%), By Region, 2018-2032F
  • Figure 8. North America Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 9. North America Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 10. North America Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 11. North America Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 12. North America Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 13. North America Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 14. North America Stomach Cancer Treatment Market Share (%), By Country, 2018-2032F
  • Figure 15. United States Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. United States Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 17. United States Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 18. United States Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 19. United States Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 20. United States Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 21. Canada Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 22. Canada Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 23. Canada Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 24. Canada Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Canada Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Canada Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Mexico Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 28. Mexico Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 29. Mexico Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 30. Mexico Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 31. Mexico Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Mexico Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 34. Europe Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 35. Europe Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 36. Europe Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 37. Europe Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Europe Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. Europe Stomach Cancer Treatment Market Share (%), By Country, 2018-2032F
  • Figure 40. Germany Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. Germany Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 42. Germany Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 43. Germany Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 44. Germany Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 45. Germany Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 46. France Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. France Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 48. France Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 49. France Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 50. France Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 51. France Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Italy Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Italy Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 54. Italy Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 55. Italy Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 56. Italy Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 57. Italy Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 58. United Kingdom Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 59. United Kingdom Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 60. United Kingdom Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 61. United Kingdom Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. United Kingdom Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. United Kingdom Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Russia Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Russia Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 66. Russia Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 67. Russia Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 68. Russia Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 69. Russia Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 70. Netherlands Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 71. Netherlands Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 72. Netherlands Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 73. Netherlands Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 74. Netherlands Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 75. Netherlands Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 76. Spain Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 77. Spain Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 78. Spain Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 79. Spain Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 80. Spain Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 81. Spain Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 82. Turkey Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. Turkey Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 84. Turkey Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 85. Turkey Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 86. Turkey Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 87. Turkey Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 88. Poland Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 89. Poland Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 90. Poland Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 91. Poland Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 92. Poland Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 93. Poland Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. South America Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. South America Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 96. South America Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 97. South America Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 98. South America Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. South America Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. South America Stomach Cancer Treatment Market Share (%), By Country, 2018-2032F
  • Figure 101. Brazil Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. Brazil Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 103. Brazil Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 104. Brazil Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 105. Brazil Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 106. Brazil Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 107. Argentina Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 108. Argentina Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 109. Argentina Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 110. Argentina Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 111. Argentina Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 112. Argentina Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 113. Asia-Pacific Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 114. Asia-Pacific Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 115. Asia-Pacific Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 116. Asia-Pacific Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 117. Asia-Pacific Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 118. Asia-Pacific Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 119. Asia-Pacific Stomach Cancer Treatment Market Share (%), By Country, 2018-2032F
  • Figure 120. India Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. India Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 122. India Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 123. India Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 124. India Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 125. India Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. China Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. China Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 128. China Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 129. China Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 130. China Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 131. China Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 132. Japan Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 133. Japan Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 134. Japan Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 135. Japan Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 136. Japan Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 137. Japan Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 138. Australia Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 139. Australia Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 140. Australia Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 141. Australia Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 142. Australia Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 143. Australia Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 144. Vietnam Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 145. Vietnam Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 146. Vietnam Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 147. Vietnam Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 148. Vietnam Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 149. Vietnam Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 150. South Korea Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 151. South Korea Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 152. South Korea Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 153. South Korea Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 154. South Korea Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 155. South Korea Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 156. Indonesia Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 157. Indonesia Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 158. Indonesia Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 159. Indonesia Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 160. Indonesia Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. Indonesia Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. Philippines Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 163. Philippines Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 164. Philippines Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 165. Philippines Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 166. Philippines Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 167. Philippines Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 168. Middle East & Africa Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 169. Middle East & Africa Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 170. Middle East & Africa Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 171. Middle East & Africa Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 172. Middle East & Africa Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 173. Middle East & Africa Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 174. Middle East & Africa Stomach Cancer Treatment Market Share (%), By Country, 2018-2032F
  • Figure 175. Saudi Arabia Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 176. Saudi Arabia Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 177. Saudi Arabia Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 178. Saudi Arabia Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 179. Saudi Arabia Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 180. Saudi Arabia Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 181. UAE Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 182. UAE Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 183. UAE Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 184. UAE Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 185. UAE Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 186. UAE Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 187. South Africa Stomach Cancer Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 188. South Africa Stomach Cancer Treatment Market Share (%), By Treatment Type, 2018-2032F
  • Figure 189. South Africa Stomach Cancer Treatment Market Share (%), By Type, 2018-2032F
  • Figure 190. South Africa Stomach Cancer Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 191. South Africa Stomach Cancer Treatment Market Share (%), By Route of Administration, 2018-2032F
  • Figure 192. South Africa Stomach Cancer Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 193. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 194. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024